Alpha-type-1 polarized dendritic cell vaccine (Roswell Park Cancer Institute)

N/A

Report date: 2022/12/19 14:23:50

Base Information

Drug NameAlpha-type-1 polarized dendritic cell vaccine (Roswell Park Cancer Institute)
Drug Alias NameaDC1 vaccineAlpha-1极化树突细胞疫苗-美国国家罗斯维尔公园癌症研究所AlphaDC1 vaccinealphaDC1CMV-alphaDC1
ClassificationVaccines > Development/production technology > Dendritic cell vaccineCell and gene therapy > Cell therapy > Immune system cell therapy > Dendritic cell therapy > Dendritic cell vaccineVaccines > Application > Prophylactic vaccine
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsHematologic NeoplasmsTriple Negative Breast NeoplasmsBreast Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRoswell Park Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesRoswell Park Cancer Institute
Inactive CompaniesN/A
Active IndicationsMelanoma
Inactive IndicationsHematologic NeoplasmsTriple Negative Breast NeoplasmsBreast Neoplasms +[4] 

Other Information

ATC CodeN/A
Related LinksN/A